Anti | 合法藥品大搜索

2016年2月11日—Rho(D)immuneglobulinorAnti-D(Rho)Immunoglobulinpreventsantibodyformationinrhesusnegativewomen.ReadaboutAnti-D(Rho) ...

The development of anti-D antibodies generally results from feto-maternal haemorrhage (FMH) occurring in rhesus D (RhD)-negative women who carry an RhD-positive fetus. In later pregnancies, anti-D antibodies can cross the placenta, causing worsening rhesus haemolytic disease with each successive rhesus-positive pregnancy.

All RhD-negative pregnant women who do not have immune anti-D, should be offered additional routine prophylaxis with anti-D immunoglobulin (anti-D Ig) during the third trimester of pregnancy1 .

For further information on the aetiology, epidemiology, presentation, investigation and differential diagnosis, see the separate Haemolytic Disease of the Fetus and Newborn[1] article.

Preparations licensed for use in the UK are:

D-GAM® (Bio Products Laboratory): available as 250, 500 and 1500 IU vials, for intramuscular use only.

Rhophylac® (ZLB Behring): available as 1500 IU prefilled syringe, for intramuscular (IM) or intravenous (IV) use.